Tumor necrosis factor α‐mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin
Top Cited Papers
Open Access
- 7 March 2002
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 46 (3) , 785-792
- https://doi.org/10.1002/art.10097
Abstract
Objective To study the effects of osteoclast‐targeted therapies, such as osteoprotegerin (OPG) and pamidronate, on joint inflammation and bone destruction using a tumor necrosis factor α (TNFα)‐transgenic mouse model. Methods Mice were placed into 5 groups that received either OPG, pamidronate, a combination of both agents, infliximab as a positive control, or phosphate buffered saline as a negative control. Treatment was initiated at the onset of arthritis, continued over 6 weeks, and thereafter, the clinical, radiologic, and histologic outcomes were assessed. Results A significant improvement in clinical symptoms, as assessed by the reduction of paw swelling, was only found in the infliximab group, whereas all other treatment groups failed to show significant improvement. However, when assessing structural damage with radiographic analysis, a significant retardation of joint damage was evident in animals treated with OPG (55% reduction of erosions), pamidronate (50% reduction of erosions) the combination therapy of OPG and pamidronate (64% reduction of erosions), and with infliximab (66% reduction of erosions). Confirming these data, quantitative histologic analysis revealed a significant reduction in the size of bone erosions in all treatment groups (OPG 56%, pamidronate 53%, OPG and pamidronate 81%, and infliximab 46%) compared with the control group. Furthermore, a significant reduction of osteoclast numbers was seen in animals treated with OPG alone or in combination with pamidronate as well as in animals treated with infliximab. Conclusion These data suggest that OPG alone or in combination with bisphosphonates is an effective therapeutic tool for the prevention of TNFα‐mediated destruction of bone by reducing the number of bone‐resorbing cells in the inflammatory tissue.Keywords
Funding Information
- Interdisciplinary Cooperative Project of the Austrian Ministry of Sciences
- City of Vienna
This publication has 44 references indexed in Scilit:
- Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)Journal of Biological Chemistry, 2000
- Pathogenesis of bone erosions in rheumatoid arthritisCurrent Opinion in Rheumatology, 2000
- Systemic Characteristics of Chronic Arthritis Induced by Transfer of Human Rheumatoid Synovial Membrane into SCID Mice (Human/Murine SCID Arthritis)Journal of Autoimmunity, 1999
- A New Member of Tumor Necrosis Factor Ligand Family, ODF/OPGL/TRANCE/RANKL, Regulates Osteoclast Differentiation and FunctionBiochemical and Biophysical Research Communications, 1999
- MECHANISMS OF ACTION OF BISPHOSPHONATESAnnual Review of Pharmacology and Toxicology, 1998
- A New Mechanism of Bone Destruction in Rheumatoid Arthritis: Synovial Fibroblasts Induce OsteoclastogenesisBiochemical and Biophysical Research Communications, 1997
- Selective activation of the JNK/AP‐1 pathway in FAS‐mediated apoptosis of rheumatoid arthritis synoviocytesArthritis & Rheumatism, 1997
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996
- Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritisArthritis & Rheumatism, 1995
- LOCALIZATION OF INTERLEUKIN-1α, TYPE 1 INTERLEUKIN-1 RECEPTOR AND INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE SYNOVIAL MEMBRANE AND CARTILAGE/PANNUS JUNCTION IN RHEUMATOID ARTHRITISRheumatology, 1992